title: Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
abstract: BACKGROUND
  This systematic review addresses the question "What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer?"
  
  
  METHODS
  The medline and embase databases were searched for the period January 2008 to May 2014. The Standards and Guidelines Evidence directory of cancer guidelines and the Web sites of major guideline organizations were also searched.
  
  
  RESULTS
  Sixty publications relevant to the targeted therapy portion of the systematic review were identified. In four major trials (hera, National Surgical Adjuvant Breast and Bowel Project B-31, North Central Cancer Treatment Group N9831, and Breast Cancer International Research Group 006), adjuvant trastuzumab for 1 year was superior in disease-free survival (dfs) and overall survival (os) to no trastuzumab; trastuzumab showed no benefit in one trial (pacs 04). A shorter duration of trastuzumab (less than 1 year compared with 1 year) was evaluated, with mixed results for dfs: one trial showed superiority (finher), one trial could not demonstrate noninferiority (phare), another trial showed equivalent results (E 2198), and one trial is still ongoing (persephone). Longer trastuzumab duration (hera: 2 years vs. 1 year) showed no improvement in dfs or os and a higher rate of cardiac events. Newer her2-targeted agents (lapatinib, pertuzumab, T-DM1, neratinib) have been or are still being evaluated in both adjuvant and neoadjuvant trials, either by direct comparison with trastuzumab alone or combined with trastuzumab. In the neoadjuvant setting (neoaltto, GeparQuinto, Neosphere), trastuzumab alone or in combination with another anti-her2 agent (lapatinib, pertuzumab) was compared with either lapatinib or pertuzumab alone and showed superior or equivalent rates of pathologic complete response. In the adjuvant setting, lapatinib alone or in combination with trastuzumab, compared with trastuzumab alone (altto) or with placebo (teach), was not superior in dfs. The results of the completed aphinity trial, evaluating the role of dual her2 blockade with trastuzumab and pertuzumab, are highly anticipated. Ongoing trials are evaluating trastuzumab as a single agent without adjuvant chemotherapy (respect) and in patients with low her2 expression (National Surgical Adjuvant Breast and Bowel Project B-47).
  
  
  CONCLUSIONS
  Taking into consideration disease characteristics and patient preference, 1 year of trastuzumab should be offered to all patients with her2-positive breast cancer who are receiving adjuvant chemotherapy. Cardiac function should be regularly assessed in this patient population.
authors.affiliation: Cancer Centre of Southeastern Ontario, Kinston General Hospital; and Queen's University, Kingston, ON.
authors.forename: M
authors.initials: M
authors.lastname: Mates
authors.affiliation: Program in Evidence-Based Care, Cancer Care Ontario; and Department of Oncology, McMaster University, Hamilton, ON.
authors.forename: G G
authors.initials: GG
authors.lastname: Fletcher
authors.affiliation: Durham Regional Cancer Centre, Oshawa, ON.
authors.forename: O C
authors.initials: OC
authors.lastname: Freedman
authors.affiliation: Sunnybrook Health Science Centre, Toronto, ON.
authors.forename: A
authors.initials: A
authors.lastname: Eisen
authors.affiliation: Sunnybrook Health Science Centre, Toronto, ON.
authors.forename: S
authors.initials: S
authors.lastname: Gandhi
authors.affiliation: Sunnybrook Health Science Centre, Toronto, ON.
authors.forename: M E
authors.initials: ME
authors.lastname: Trudeau
authors.affiliation: The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON.
authors.forename: S F
authors.initials: SF
authors.lastname: Dent
keywords: Early breast cancer; her2; lapatinib; pertuzumab; targeted therapy; trastuzumab
references.citation: Lancet. 2007 Jan 6;369(9555):29-36
references.pmid: 17208639
references.citation: J Clin Oncol. 2011 Dec 1;29(34):4491-7
references.pmid: 22042958
references.citation: Lancet Oncol. 2013 Jul;14(8):741-8
references.pmid: 23764181
references.citation: Lancet Oncol. 2012 Feb;13(2):135-44
references.pmid: 22257523
references.citation: J Clin Oncol. 2012 Nov 1;30(31):3792-9
references.pmid: 22987084
references.citation: Cancer Treat Rev. 2008 Oct;34(6):539-57
references.pmid: 18502589
references.citation: J Clin Oncol. 2013 Dec 20;31(36):4504-11
references.pmid: 24248687
references.citation: J Clin Oncol. 2010 Oct 1;28(28):4307-15
references.pmid: 20697084
references.citation: Cancer Treat Rev. 2011 Jun;37(4):312-20
references.pmid: 20952131
references.citation: Cancer. 2010 Jun 15;116(12):2856-67
references.pmid: 20564392
references.citation: Trials. 2013 Aug 19;14:261
references.pmid: 23958221
references.citation: N Engl J Med. 2011 Oct 6;365(14):1273-83
references.pmid: 21991949
references.citation: Breast. 2011 Dec;20(6):485-90
references.pmid: 21784637
references.citation: Clin Cancer Res. 2007 Jan 1;13(1):228-33
references.pmid: 17200359
references.citation: J Clin Oncol. 2014 Jul 10;32(20):2159-65
references.pmid: 24912899
references.citation: Lancet Oncol. 2012 Jan;13(1):25-32
references.pmid: 22153890
references.citation: Ann Oncol. 2011 Sep;22(9):2007-13
references.pmid: 21285132
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: BMC Med Res Methodol. 2007 Feb 15;7:10
references.pmid: 17302989
references.citation: Oncologist. 2013;18(7):812-8
references.pmid: 23814044
references.citation: Lancet Oncol. 2013 Jan;14(1):88-96
references.pmid: 23234763
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3366-73
references.pmid: 21768458
references.citation: Jpn J Clin Oncol. 2011 May;41(5):709-12
references.pmid: 21355003
references.citation: J Clin Oncol. 2011 Feb 20;29(6):651-9
references.pmid: 21245420
references.citation: Ann Oncol. 2011 Feb;22(2):301-6
references.pmid: 20624784
references.citation: Lancet Oncol. 2011 Mar;12(3):236-44
references.pmid: 21354370
references.citation: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243
references.pmid: 22513938
references.citation: Lancet. 2013 Sep 21;382(9897):1021-8
references.pmid: 23871490
references.citation: Lancet Oncol. 2013 Dec;14(13):1317-25
references.pmid: 24239210
references.citation: N Engl J Med. 2005 Oct 27;353(17 ):1784-92
references.pmid: 16251534
references.citation: PLoS One. 2011;6(6):e21030
references.pmid: 21695277
references.citation: Lancet. 2012 Feb 18;379(9816):633-40
references.pmid: 22257673
references.citation: J Natl Cancer Inst. 2012 Jan 18;104(2):159-62
references.pmid: 22138096
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6129-34
references.pmid: 19917839
references.citation: Cancer Treat Rev. 2013 Oct;39(6):622-31
references.pmid: 23434074
references.citation: Ann Oncol. 2010 Nov;21(11):2153-60
references.pmid: 20351072
references.citation: Med Oncol. 2011 Jun;28(2):401-8
references.pmid: 20195801
references.citation: Lancet Oncol. 2013 Mar;14(3):244-8
references.pmid: 23414588
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5685-92
references.pmid: 19884557
references.citation: Anticancer Drugs. 2011 Feb;22(2):128-35
references.pmid: 21218604
references.citation: Clin Oncol (R Coll Radiol). 2009 Apr;21(3):159-60
references.pmid: 19167201
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1231-8
references.pmid: 18250349
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3628-36
references.pmid: 12202663
references.citation: Ann Oncol. 2008 Jun;19(6):1090-6
references.pmid: 18296421